1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers

CDK2, CDK4, CDK2/4/6 Drugs Now In Early Trials

 
• By Mandy Jackson

Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.

Digital 3d illustration of cancer cells in human body
Pfizer looks to strengthen its breast cancer position with additional CDK inhibitors • Source: Shutterstock

Pfizer Inc. is moving forward quickly with clinical development of three new CDK inhibitors to build on its Ibrance (palbociclib) breast cancer franchise – at a time when sales of competing CDK4/6 inhibitors are soaring.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.